Beam Therapeutics Inc.: shareholders and insiders

BEAMNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$20.65

November 17, 2026Market cap $2.1B

What Ploutos Investor adds for Beam Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 22% since Nov 3, 2026, when the 10-Q these figures come from was filed ($26.33 then, $20.65 on Nov 17, 2026). The figures date from before that move.10-Q

Insiders and their shares

Purchases and sales by officers and directors from Nov 18, 2025 to Oct 16, 2026, from their own Form 4 filings.

14 Form 4s

Bought on the market

–

nobody

Sold on the market

$20M

7 people

From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan49%
  • The rest51%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $20M by 6 people

  • 2025: no buys, sold $204.6K by 2 people
  • 2026: no buys, sold $20M by 6 people
  • Oct 16, 2026John M. EvansCEO
    Kind10b5-1
  • Oct 16, 2026John M. EvansCEO
    Kind10b5-1
  • Oct 15, 2026John M. EvansCEO
    Kind10b5-1
  • Oct 15, 2026John M. EvansCEO
    Kind10b5-1
  • Oct 1, 2026Bethany J CavanaghSVP, Finance and Treasurer
    Kind10b5-1
  • Sep 24, 2026Giuseppe CiaramellaPresident
    Kind
  • Jul 27, 2026Amy SimonChief Medical Officer
    Kind10b5-1
  • Jun 30, 2026Amy SimonChief Medical Officer
    Kind10b5-1
  • Jun 30, 2026John M. EvansCEO
    Kind10b5-1
  • Jun 30, 2026John M. EvansCEO
    Kind10b5-1
  • Jun 30, 2026John M. EvansCEO
    Kind10b5-1
  • Jun 29, 2026John M. EvansCEO
    Kind10b5-1
  • Jun 29, 2026John M. EvansCEO
    Kind10b5-1
  • Jun 29, 2026John M. EvansCEO
    Kind10b5-1
  • Jun 29, 2026John M. EvansCEO
    Kind10b5-1
  • Jun 26, 2026Fmr Llc
    Kind
  • Jun 25, 2026Fmr Llc
    Kind
  • Jun 17, 2026Giuseppe CiaramellaPresident
    Kind
  • Jun 17, 2026Giuseppe CiaramellaPresident
    Kind
  • Apr 1, 2026Giuseppe CiaramellaPresident
    Kind10b5-1
  • Apr 1, 2026Christine BellonChief Legal Officer
    Kind10b5-1
  • Apr 1, 2026Bethany J CavanaghSVP, Finance and Treasurer
    Kind10b5-1
  • Apr 1, 2026Amy SimonChief Medical Officer
    Kind10b5-1
  • Apr 1, 2026John M. EvansCEO
    Kind10b5-1
  • Mar 31, 2026John M. EvansCEO
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 5, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by BEAM's officers and directors from 2020 up to November 17, 2025, 6 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

6 Holders over 5%Aug 14, 2026 Latest filing
  • FMRwith 1 more person
    Share of class12.6%
  • Farallon Capital Management, L.L.C.with 28 more persons
    Share of class9.99%
  • ARK Investment Management LLCwith 1 more person
    Share of class9.95%
  • BlackRock, Inc.
    Share of class7.50%
  • State Street
    Share of class5.20%
  • Vanguard Capital Management
    Share of class5.02%
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 26, 202613G/A
  • ARCH Venture Fund IX, L.P.4.60%May 15, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Duquesne (Druckenmiller)
    In the quarter+356%
  • Renaissance Technologies
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-34%
  • D.E. Shaw
    In the quarter
  • AQR Capital
    In the quarter-8.3%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 25.8% of its shares outstanding were held short, -4.7% since the report before.

Shares held short
26.24M
25.8%
Since the report before27.55M on Sep 30, 2026
-4.7%
14.1
1.86M
More days to cover thanof 4,578 US-listed companies with enough volume
97%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 14.45M
  • Nov 15, 2023: Shares held short 13.83M
  • Nov 30, 2023: Shares held short 13.00M
  • Dec 15, 2023: Shares held short 13.48M
  • Dec 29, 2023: Shares held short 13.49M
  • Jan 12, 2024: Shares held short 13.13M
  • Jan 31, 2024: Shares held short 13.39M
  • Feb 15, 2024: Shares held short 13.43M
  • Feb 29, 2024: Shares held short 13.11M
  • Mar 15, 2024: Shares held short 14.32M
  • Mar 28, 2024: Shares held short 13.45M
  • Apr 15, 2024: Shares held short 13.17M
  • Apr 30, 2024: Shares held short 14.02M
  • May 15, 2024: Shares held short 14.58M
  • May 31, 2024: Shares held short 13.83M
  • Jun 14, 2024: Shares held short 12.95M
  • Jun 28, 2024: Shares held short 11.80M
  • Jul 15, 2024: Shares held short 12.06M
  • Jul 31, 2024: Shares held short 11.62M
  • Aug 15, 2024: Shares held short 11.18M
  • Aug 30, 2024: Shares held short 11.08M
  • Sep 13, 2024: Shares held short 10.96M
  • Sep 30, 2024: Shares held short 11.36M
  • Oct 15, 2024: Shares held short 11.16M
  • Oct 31, 2024: Shares held short 12.31M
  • Nov 15, 2024: Shares held short 11.97M
  • Nov 29, 2024: Shares held short 10.68M
  • Dec 13, 2024: Shares held short 10.06M
  • Dec 31, 2024: Shares held short 9.83M
  • Jan 15, 2025: Shares held short 10.79M
  • Jan 31, 2025: Shares held short 10.02M
  • Feb 14, 2025: Shares held short 9.24M
  • Feb 28, 2025: Shares held short 9.99M
  • Mar 14, 2025: Shares held short 12.16M
  • Mar 31, 2025: Shares held short 14.74M
  • Apr 15, 2025: Shares held short 18.83M
  • Apr 30, 2025: Shares held short 19.26M
  • May 15, 2025: Shares held short 20.84M
  • May 30, 2025: Shares held short 21.16M
  • Jun 13, 2025: Shares held short 21.73M
  • Jun 30, 2025: Shares held short 24.08M
  • Jul 15, 2025: Shares held short 23.66M
  • Jul 31, 2025: Shares held short 24.62M
  • Aug 15, 2025: Shares held short 27.17M
  • Aug 29, 2025: Shares held short 25.48M
  • Sep 15, 2025: Shares held short 25.50M
  • Sep 30, 2025: Shares held short 21.38M
  • Oct 15, 2025: Shares held short 20.42M
  • Oct 31, 2025: Shares held short 19.82M
  • Nov 14, 2025: Shares held short 20.55M
  • Nov 28, 2025: Shares held short 20.95M
  • Dec 15, 2025: Shares held short 19.79M
  • Dec 31, 2025: Shares held short 20.30M
  • Jan 15, 2026: Shares held short 20.04M
  • Jan 30, 2026: Shares held short 19.41M
  • Feb 13, 2026: Shares held short 20.23M
  • Feb 27, 2026: Shares held short 21.89M
  • Mar 13, 2026: Shares held short 21.30M
  • Mar 31, 2026: Shares held short 23.36M
  • Apr 15, 2026: Shares held short 22.22M
  • Apr 30, 2026: Shares held short 20.94M
  • May 15, 2026: Shares held short 26.52M
  • May 29, 2026: Shares held short 21.46M
  • Jun 15, 2026: Shares held short 28.31M
  • Jun 30, 2026: Shares held short 22.88M
  • Jul 15, 2026: Shares held short 23.22M
  • Jul 31, 2026: Shares held short 23.50M
  • Aug 14, 2026: Shares held short 24.37M
  • Aug 31, 2026: Shares held short 25.80M
  • Sep 15, 2026: Shares held short 25.88M
  • Sep 30, 2026: Shares held short 27.55M
  • Oct 15, 2026: Shares held short 26.24M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading63.7% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 63.7% of the shares in the reported trades were short sales, against 58.6% in the 14 before.

Last 14 sessionsOct 29, 2026 – Nov 17, 2026
63.7%
The 14 beforeOct 9, 2026 – Oct 28, 2026
58.6%
Change
+5.1 pts
Short sales a dayon average, of 809.3K shares
515.5K
More than atof 3,666 US-listed companies, same days
90%
Median of alleight in ten from 34.6% to 63.7%
50.3%
  • Oct 9, 2026: Short sales 49.3%
  • Oct 12, 2026: Short sales 57.3%
  • Oct 13, 2026: Short sales 62.4%
  • Oct 14, 2026: Short sales 55.2%
  • Oct 15, 2026: Short sales 59.8%
  • Oct 16, 2026: Short sales 67.7%
  • Oct 19, 2026: Short sales 65.1%
  • Oct 20, 2026: Short sales 58.4%
  • Oct 21, 2026: Short sales 44.2%
  • Oct 22, 2026: Short sales 70.3%
  • Oct 23, 2026: Short sales 64.8%
  • Oct 26, 2026: Short sales 41.8%
  • Oct 27, 2026: Short sales 46.9%
  • Oct 28, 2026: Short sales 65%
  • Oct 29, 2026: Short sales 52%
  • Oct 30, 2026: Short sales 62.6%
  • Nov 2, 2026: Short sales 65.4%
  • Nov 3, 2026: Short sales 69.5%
  • Nov 4, 2026: Short sales 63.7%
  • Nov 5, 2026: Short sales 49.9%
  • Nov 6, 2026: Short sales 60%
  • Nov 9, 2026: Short sales 55.5%
  • Nov 10, 2026: Short sales 76.5%
  • Nov 11, 2026: Short sales 56.6%
  • Nov 12, 2026: Short sales 73.1%
  • Nov 13, 2026: Short sales 69%
  • Nov 16, 2026: Short sales 64.2%
  • Nov 17, 2026: Short sales 66.2%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

2.65M Insiders' shares2.60% Of the company
  • John M. EvansCEO
    Directly1.15M
  • Fmr LlcTenPercentOwner,Other
    Directly–
  • Giuseppe CiaramellaPresident
    Directly253.9K
  • Christine BellonChief Legal Officer
    Directly109.7K
  • Amy SimonChief Medical Officer
    Directly85.7K
  • Sravan Kumar EmanyChief Financial Officer
    Directly73.7K
  • Terry-Ann BurrellChief Financial Officer
    Directly70.1K
  • Bethany J CavanaghSVP, Finance and Treasurer
    Directly51.0K

A lower bound: it counts only the 8 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

25 ETFs holding it3.78% The largest weight (ARKG)
  • ARKGARK Genomic Revolution ETF
    Weight in the fund3.78%
  • ARKKARK Innovation ETF
    Weight in the fund2.79%
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund1.08%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.59%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.25%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.18%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.11%
  • VBKVanguard Small-Cap Growth Index Fund
    Weight in the fund0.10%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.09%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.06%

25 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

279 Managers, Q2 2026$3.8B Value of their positions
  • Q3 2025: Managers 220
  • Q4 2025: Managers 248
  • Q1 2026: Managers 257
  • Q2 2026: Managers 279

Institutional investors by quarter

The fund managers holding BEAM, quarter by quarter, from Q1 2013 to Q2 2025, 32 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 279 managers held 109M shares, worth $3.8B. During the quarter 60 opened a position, 38 closed one, 90 added and 75 trimmed.

The largest holders, Q2 2026

  • FMR
    In the quarter+1.3%
  • Farallon Capital Management
    In the quarter+1.0%
  • ARK Investment Management
    In the quarter-16%
  • BlackRock
    In the quarter+6.0%
  • State Street
    In the quarter+2.2%
  • Vanguard Portfolio Management
    In the quarter+7.7%
  • Vanguard Capital Management
    In the quarter+5.1%
  • ARCH Venture Management
    In the quarter
  • Amova Asset Management Americas
    In the quarter-9.7%
  • Sumitomo Mitsui Trust Group
    In the quarter-9.7%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Beam Therapeutics's filings show?

Who buys and sells is one part of Beam Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about BEAM's shareholders

Didn't find what you were looking for?

Ask us
Have BEAM's insiders bought or sold?

From Jun 5, 2026 to Oct 16, 2026 Beam Therapeutics's insiders bought 0 and sold $13M of shares on the market. 25% of the sales were under set 10b5-1 plans.

Which well-known managers hold BEAM?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Duquesne (Druckenmiller)'s, worth $17M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.